<p>A) REN and B) JU77 cells were transfected with siNT, siBAX, siBAK and the combination of siBAX and siBAK. 24 h following transfection, cells were treated with a concentration of bortezomib equal to the IC<sub>50</sub> calculated for each cell line and caspase3 activity measured. Data were normalized to NT untreated control (REN: siNT p = 0.0003 siBAX p = 0.0159; siBAK n.s. siBAXsiBAK n.s.; JU77: siNT p = 0.0002 siBAX p = 0.0002; siBAK n.s.; siBAXsiBAK n.s.). C) BAX and BAK expression and PARP cleavage were confirmed by western blot analysis in REN and D) JU77 cells.</p
<p>A. Empty vector and GITR-transfected MM1.S cells were treated with Bortezomib for 48 hours. Cell ...
<p>(<b>A</b>) A panel of human MMC lines were treated with the indicated concentrations of bortezomi...
<p>(<b>A</b>) Expression of both anti-apoptotic and pro-apoptotic Bcl-2 proteins in the indicated ce...
<p>A) WT MEF and BAX/BAK DKO MEF cells were treated with bortezomib 10 nM for 24 h. PARP cleavage wa...
<p>A) REN and JU77 selected for resistance after exposure to increasing doses of bortezomib were tes...
<p>(<b>A</b>) Parental U266 cells and their bortezomib-resistant counterparts (PS-R) were exposed to...
Background: Multiple myeloma (MM), a malignancy of plasma cells, is the second most prevalent hemato...
<p><b>A</b>. K562 leukemic cells were exposed to bortezomib (9nM) with or without paclitaxel (6nM) f...
<p><b>A</b>. K562 leukemic cells were plated in 75cm<sup>2</sup> flasks (2 x 10<sup>6</sup> cells/30...
<p>(<b>A</b>) Percentage of dead DU 145 cells (annexin V<sup>+</sup>/PI<sup>-</sup> and annexin V<su...
<p>(A) Viability assay evaluated by trypan blue exclusion was performed in BC3 (left panel) and BCBL...
<p>(A) <i>MCL1<sup>−/−</sup></i> cells were transfected with Bax- and/or Bak-specific siRNAs for 2 d...
<p>(A) Immunofluorescence microscopy for active Bak and Bax in MDA-MB-231 cells stably transfected w...
<p>(A). Frequency of apoptosis of RPMI 8226 and AMO1. Left panels: dot plots showing the frequency o...
<p>PEL cells were exposed to Bortezomib, AG 490 or both for the indicated times, then resuspended in...
<p>A. Empty vector and GITR-transfected MM1.S cells were treated with Bortezomib for 48 hours. Cell ...
<p>(<b>A</b>) A panel of human MMC lines were treated with the indicated concentrations of bortezomi...
<p>(<b>A</b>) Expression of both anti-apoptotic and pro-apoptotic Bcl-2 proteins in the indicated ce...
<p>A) WT MEF and BAX/BAK DKO MEF cells were treated with bortezomib 10 nM for 24 h. PARP cleavage wa...
<p>A) REN and JU77 selected for resistance after exposure to increasing doses of bortezomib were tes...
<p>(<b>A</b>) Parental U266 cells and their bortezomib-resistant counterparts (PS-R) were exposed to...
Background: Multiple myeloma (MM), a malignancy of plasma cells, is the second most prevalent hemato...
<p><b>A</b>. K562 leukemic cells were exposed to bortezomib (9nM) with or without paclitaxel (6nM) f...
<p><b>A</b>. K562 leukemic cells were plated in 75cm<sup>2</sup> flasks (2 x 10<sup>6</sup> cells/30...
<p>(<b>A</b>) Percentage of dead DU 145 cells (annexin V<sup>+</sup>/PI<sup>-</sup> and annexin V<su...
<p>(A) Viability assay evaluated by trypan blue exclusion was performed in BC3 (left panel) and BCBL...
<p>(A) <i>MCL1<sup>−/−</sup></i> cells were transfected with Bax- and/or Bak-specific siRNAs for 2 d...
<p>(A) Immunofluorescence microscopy for active Bak and Bax in MDA-MB-231 cells stably transfected w...
<p>(A). Frequency of apoptosis of RPMI 8226 and AMO1. Left panels: dot plots showing the frequency o...
<p>PEL cells were exposed to Bortezomib, AG 490 or both for the indicated times, then resuspended in...
<p>A. Empty vector and GITR-transfected MM1.S cells were treated with Bortezomib for 48 hours. Cell ...
<p>(<b>A</b>) A panel of human MMC lines were treated with the indicated concentrations of bortezomi...
<p>(<b>A</b>) Expression of both anti-apoptotic and pro-apoptotic Bcl-2 proteins in the indicated ce...